PCI Biotech: Invitation to first-half year 2022 results presentation

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Oslo, Norway, 26 August 2022 – PCI Biotech (OSE: PCIB) invites to an online presentation of the company’s first-half year 2022 interim report on Wednesday 31 August 2022, 08:30am – 09:30am CEST (local time).

The presentation will be held as a live webcast and can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console or through a teleconference facilitated for attendees intending to ask questions verbally during the Q&A session.

PCI Biotech’s first-half year 2022 interim report will be released on 31 August 2022 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com.

For further information, please contact:
Ronny Skuggedal, Interim CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech        
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.

The fimaVacc programme aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com                
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo            

Forward-looking statements        
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Staff

Recent Posts

Newly Published Health Economics Study Demonstrates In-Office Ear Tube Procedures with Hummingbird TTS Significantly Reduce Healthcare Costs

GOLDEN VALLEY, Minn.--(BUSINESS WIRE)--Preceptis Medical, Inc., a pioneer in pediatric ENT innovation, today announced the…

1 hour ago

111, Inc. Announces First Quarter 2025 Unaudited Financial Results

Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoYMaintained…

1 hour ago

As Sober.Buzz Community Explodes Its Growth Globally it is Announcing “Spreading the Good BUZZ” Podcast Hosted by Josh Case Debuting July 7th

Sober.Buzz's Online Store that includes the Exclusive Inspirational Collection by Heidi Case has Launched. Additionally,…

13 hours ago

STUDENTS STEP INTO THE ROLE OF ATHLETIC TRAINERS, CARDIOLOGISTS, DIETITIANS, AND MORE WITH FREE SUMMER SCIENCE PROGRAM!

GSK Science in the Summer™ Unveils New 2025 Theme: Be A Health Scientist! PHILADELPHIA, June…

13 hours ago

Healthy Interactions Expands Primary Care Alliance to Improve Cardiometabolic Care

JACKSON HOLE, Wyo., June 18, 2025 /PRNewswire/ -- Healthy Interactions LLC, a global leader in…

13 hours ago